Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.
Nissan MH, Rosen N, Solit DB. ERK pathway inhibitors: how low should we go? Cancer Discov. 2013;3:719–21.
Baines AT, Xu D, Der CJ. Inhibition of RAS for cancer treatment: the search continues. Future Med Chem. 2011;3:1787–808.
Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K, et al. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br J Haematol. 2012;158:519–22.
Ward AF, Braun BS, Shannon KM. Targeting oncogenic RAS signaling in hematologic malignancies. Blood. 2012;120:3397–406.
Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, et al. Response and resistance to MEK inhibition in leukemias initiated by hyperactive RAS. Nature. 2009;461:411–4.
Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, et al. First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study. Cancer Discov. 2018;8:184–95.
Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to B-Raf and MEK inhibitors. Cancer Discov. 2013;3:742–50.
Bhagwat SV, McMillen WT, Cai S, Zhao B, Whitesell M, Kindler L, et al. Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations. Abstract 4973; Proc AACR Annual Meeting 2017; 1–5 April 2017, Washington, DC.
Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1:433–43.
Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129–41.
Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, et al. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3:173–83.
Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, et al. Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 2017;8:67639–50.
Chambard JC, Lefloch R, Pouyssegur J, Lenormand P. ERK implication in cell cycle regulation. Biochim Biophys Acta. 2007;1773:1299–310.
This work was funded by Eli Lilly and Company, and the Project Program Grant, NIH PO1CA66996.
Conflict of interest
JDG receives funding and has received a royalty payment from Novartis Pharmaceuticals and receives funding from Eli Lilly and Company. N is a founder, science advisory board member (SAB), and equity holder in Gatekeeper, Syros, Petra, C4, B2S, and Soltego. The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Janssen, Kinogen, Voronoi, Her2llc, Deerfield, and Sanofi. EW has received a royalty payment from Novartis Pharmaceuticals. RS does Ad Hoc consulting for and receives clinical research support to Dana-Farber Cancer Institute from the following companies: Abbvie, Agios, Arog, and Novartis. He does Ad Hoc consulting for the following companies: Astrazeneca, Cornerstone, Jazz, Daiichi-Sankyo, Otsuka/Astex, Pfizer, and Stemline. He is on the Advisory Board of the following companies: Actinium, Amgen, Astellas, and Macrogenics. He is on the Data Safety and Monitoring Board for the following companies: Argenx, Celgene, and Takeda. He is an Ad Hoc Consultant and on the Steering Committee and Data Safety and Monitoring Board for Celgene. SVB is an employee and shareholder of Eli Lilly and Company. RVT was an employee and is a shareholder of Eli Lilly and Company, and is currently employed by Astellas Pharma.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Weisberg, E., Meng, C., Case, A. et al. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia 34, 625–629 (2020). https://doi.org/10.1038/s41375-019-0552-3
Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia
Journal of Cellular and Molecular Medicine (2020)
TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1
Journal of Experimental & Clinical Cancer Research (2020)